Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDB1 | Q16531 | 15/20 | 0.64 |
| ▸ | CRBN | Q96SW2 | 15/20 | 0.64 |
| ▸ | IDO1 | P14902 | 5/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25955981 | 0.81 | CRBN (0.62) | DDB1CRBN | |
| SCHEMBL27284842 | 0.81 | CRBN (0.61) | DDB1CRBN | |
| SCHEMBL25575946 | 0.81 | CRBN (0.57) | DDB1CRBNIDO1 | |
| SCHEMBL26296845 | 0.80 | CRBN (0.61) | DDB1CRBN | |
| SCHEMBL24204275 | 0.80 | CRBN (0.61) | DDB1CRBN | |
| SCHEMBL25810645 | 0.79 | DDB1 (0.73) | DDB1CRBN | |
| SCHEMBL24319159 | 0.79 | DDB1 (0.56) | DDB1CRBNIDO1 | |
| SCHEMBL459725 | 0.78 | DDB1 (1.00) | DDB1CRBN | |
| SCHEMBL30484086 | 0.78 | CRBN (0.58) | DDB1CRBN | |
| SCHEMBL25831265 | 0.78 | CRBN (0.58) | DDB1CRBN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4393922-A1 | IRAK4 DEGRADATION AGENT, AND PREPARATION METHOD THEREFOR AND USE THEREOF | Shanghai Leadingtac Pharmaceutical Co. Ltd. (CN) | 2024-07-03 | — | — | EP | disclosed |
| EP-4328219-A1 | SOS1 DEGRADING AGENT AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | Shanghai Leadingtac Pharmaceutical Co. Ltd. (CN) | 2024-02-28 | — | — | EP | disclosed |
| US-20230234936-A1 | COMPOUND FOR TARGETING AND DEGRADING PROTEIN, AND PREPARATION METHOD THEREFOR AND USE THEREOF | LEADINGTAC PHARMACEUTICAL (SHAOXING) CO., LTD. (CN) | 2023-07-27 | — | — | US | disclosed |
| EP-4194457-A1 | COMPOUND FOR TARGETING AND DEGRADING PROTEIN, AND PREPARATION METHOD THEREFOR AND USE THEREOF | Shanghai Leadingtac Pharmaceutical Co., Ltd. (CN) | 2023-06-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230234936-A1 | COMPOUND FOR TARGETING AND DEGRADING PROTEIN, AND PREPARATION METHOD THEREFOR AND USE THEREOF | IRAK4, IRAK2, IRAK1 | DDB1 1973/4885CRBN 221/4885IDO1 1861/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.